Prostate Specific Antigen, Complexed
Also known as: PSA COMP
Use
This test is used as an aid in the detection of prostate cancer in men age 50 and older when used in conjunction with a digital rectal exam. It is also utilized for managing and monitoring prostate cancer patients. The test helps in differentiating between prostate cancer and other prostatic conditions, as its levels are usually not elevated in healthy individuals or non-prostatic carcinoma cases. However, elevated levels can occur in benign prostatic hyperplasia or inflammatory conditions of the prostate. Careful interpretation is required for patients under treatment with antiandrogens and LHRH agonists and antagonists, as they may show reduced levels of cPSA.
Special Instructions
Not provided.
Limitations
Results from different assay methods or kits cannot be used interchangeably. cPSA is not elevated in healthy men or with non-prostatic carcinoma, and results may be affected by benign prostatic hyperplasia or inflammatory prostate conditions. Prostate cancer patients under treatment with antiandrogens and LHRH agonists/antagonists may have reduced levels of cPSA, requiring careful interpretation.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
PSA Complexed
Protein
LOINC Codes
- 33667-7 - Complexed PSA SerPl-mCnc
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.0 mL
Minimum Volume
0.5 mL
Container
Plain red or serum separator tube.
Storage Instructions
Refrigerated.
Causes for Rejection
Hemolyzed specimens. Any specimens other than serum.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |
Other tests from different labs that may be relevant